Transcript Sepsis Self
Continuing Education Credit Date of Release: 6/15/2015 Date of Expiration: 6/14/2016 Estimated time to complete this educational activity: 1 hour Continuing Education Credit • Physicians - This program has been reviewed and is acceptable for up to one (1.0) prescribed credit hour by the American Academy of Family Physicians. AAFP prescribed credit is accepted by the AMA as equivalent to AMA PRA Category I for the AMA Physicians‘ Recognition Award. When applying for the AMA PRA, prescribed hours earned must be reported as prescribed hours, not as Category I. • Nursing - Educational Review Systems is an approved provider of continuing education in nursing by ASNA, an accredited provider by the ANCC/Commission on Accreditation. Provider #5-115. This program is approved for one (1.0) hour. Educational Review Systems is also approved for nursing continuing education by the State of California and the District of Columbia. • Respiratory Therapy - This program has been approved for 1 contact hours Continuing Respiratory Care Education (CRCE) credit by the American Association for Respiratory Care, 9425 N. MacArthur Blvd. Suite 100 Irving TX 75063 Course # 213078000 • Laboratory Technicians - One PACE credit will be provided for this self-study program. This session is approved for 1 Florida CE credit. Florida Board of Clinical Laboratory Personnel approved number: 50-12563. Statement of Need Sepsis kills more than 210,000 Americans each year and is becoming more common, especially in the hospital. Sepsis is a medical emergency that can be difficult to define, diagnose, and treat, but every minute counts in the effort to save lives. This learning activity will describe how bedside analyte testing could aid therapeutic decision making and improve the prognosis for patients with sepsis. Intended Audience The primary audience for this learning activity are health care professionals (physicians and nurses) who are involved in the testing, diagnosis, treatment, and management of sepsis and are interested in the role of biomarkers to improve the care for these patients. Learning Objectives After completing this activity, the participant should be able to: 1. Review the epidemiology of sepsis. 2. Describe biomarkers used in the diagnosis and treatment of sepsis. 3. Explain how to evaluate sepsis tests and results. 4. Identify the benefits of point-of-care analyte testing in sepsis patients. Medical Advisement We would like to acknowledge the following medical experts who served as advisors to this educational program: Emanuel P. Rivers, MD, MPH Thomas Ahrens, DNS, RN, PhD Arthur P. Wheeler, MD Jill A. Sellers, BSPharm, PharmD Disclosures Thomas Ahrens, DNS, RN, PhD No financial relationships to disclose. Emanuel P. Rivers, MD, MPH No financial relationships to disclose. Jill A. Sellers, BSPharm, PharmD No financial relationships to disclose. Arthur P. Wheeler, MD No financial relationships to disclose. Introduction to Sepsis Definition, Etiology, Morbidity and Mortality Sepsis “Hectic fever, at its inception, is difficult to recognize but easy to treat; left unattended it becomes easy to recognize and difficult to treat.” ~ Niccolo Machiavelli The Prince (1513) Definition of Sepsis • Sepsis – Systemic response to infection – Manifested by two or more SIRS criteria as a result of proven or suspected infection • Temperature ≥ 38C or ≤ 36C • HR ≥ 90 beats/min • Respirations ≥ 20/min • WBC count ≥ 12,000/mm3 or ≤ 4,000/mm3 or > 10% bands • PaCO2 < 32 mmHg ACCP/SCCM Consensus Conference. Crit Care Med. 1992;20(6):864-74. Case Study Case Study: Mr. Z • Mr. Z is a 47 year-old male who was admitted to the emergency department. He is complaining of a toothache that has been present for 7 days. • His tooth pain is severe and he came to the emergency department since he could not see his dentist until the morning. He has drainage from tooth #20, for which a culture has been obtained and sent to the lab. • He tells you “My tooth is killing me! You can pull it if you need to. I feel like it is going to explode.” Case Study: Mr. Z • Mr. Z is alert and oriented. • He has a history of hypertension and had a hemorrhagic stroke 10 years ago but has had no major health issues since this time. • His heart and lung sounds are normal and his skin is cool and moist. He has good capillary refill, abdomen soft and non-tender. • He is currently on Cefoxitin (Mefoxin) 2 g IV q6h. Case Study: Mr. Z Admission Heart Rate 111 Temperature 38.7 SPO2 0.96 NIBP 128/88 (101) Respiratory Rate 22 SPO2: Pulse oximetry oxygen saturation; NIBP: Non-invasive blood pressure Questions 1) Does Mr. Z have signs of sepsis? Yes 2) What is a blood test that would be useful? Lactate Case Study: Mr. Z Admission Heart Rate Temperature SPO2 NIBP Respiratory Rate Serum Lactate 111 38.7 0.96 128/88 (101) 22 3.5 After 20 mL/kg normal saline (10 minutes) Heart Rate 104 Temperature 38.6 SPO2 0.96 NIBP 130/88 (102) Respiratory Rate 22 Case Study: Mr. Z After 4 Hours Heart Rate 88 Temperature 38.1 SPO2 0.98 NIBP 133/78 (94) Respiratory Rate 17 Serum Lactate 1.8 • A decrease in lactate shows improved perfusion. • If the lactate had remained elevated, more fluids could have been given. • The use of the lactate allowed the clinician to better evaluate the seriousness of the situation. • Often, vital signs are normal when lactates are elevated. Sepsis is Serious. • Sepsis is a serious medical condition caused by an overwhelming immune response to infection. • Complex chain of events: – Inflammatory and anti-inflammatory processes – Humoral and cellular reactions – Circulatory abnormalities • Results in impaired blood flow, which damages organs by depriving them of nutrients and oxygen. http://www.nigms.nih.gov/Education/factsheet_sepsis.htm The Intracellular Immune Response to Infection Adapted from Holmes CL, Russell JA, Walley KR. Chest. 2003;124:1103-15. Symptoms of Sepsis • Sepsis can begin in different parts of the body and can have many different symptoms. • Rapid breathing and a change in mental status, may be the first signs of sepsis. • Other symptoms include: – Fever – Chills/hypothermia – Decreased urination – Tachycardia – Nausea and vomiting The Sepsis Continuum Infection/Trauma Local or systemic infection or traumatic injury SIRS A clinical response arising from a nonspecific insult, including ≥ 2 of the following: Sepsis SIRS with a presumed or confirmed infection • Temperature > 38ºC or < 36ºC • Heart rate > 90 beats/min • Respiratory rate > 20 breaths/min or PaCO2 < 32 Torr • WBC > 12,000 cells/mm3, < 4,000 cells/mm3, or > 10% immature Severe Sepsis Sepsis with ≥ 1 sign of organ failure: • Cardiovascular (refractory hypotension) • Renal • Respiratory • Hepatic • Hematologic • CNS • Unexplained metabolic acidosis Adapted from Bone RC, Balk RA, Cerra FB et al. Chest. 1992;101:1644-55. The Relationship Between SIRS, Sepsis, and Severe Sepsis Other Sepsis Pancreatitis Infection Severe Sepsis SIRS Trauma Burns Bone RC, Balk RA, Cerra FB et al. Chest. 1992;101:1644-55. Locations for Common Infection Lungs Skin and soft tissue Vascular Catheters (endovascular) Abdomen Appendix http://www.nigms.nih.gov/Education/factsheet_sepsis.htm Urinary Tract Microbes • Many different types of microbes can cause sepsis: – Bacteria (most common) – Fungi – Viruses • Severe cases often result from a localized infection but sepsis can also spread throughout the body. Staphylococcus sp. (Bacteria) CDC/ Matthew J. Arduino Aspergillus sp. (Fungi) CDC/ Robert Simmons http://www.nigms.nih.gov/Education/factsheet_sepsis.htm Influenza (Virus) CDC/ Erskine. L. Palmer, PhD; M. L. Martin Mortality Rates • Sepsis remains the leading cause of death in critically ill patients in the United States. • Each year 750,000 people will develop sepsis. Deaths Per Year 250,000 200,000 150,000 100,000 50,000 0 AIDS Breast Cancer Severe Sepsis National Center for Health Statistics, 2001. American Cancer Society, 2001. Angus DC, Linde-Zwirble WT, Lidicker J et al. Crit Care Med. 2001;29(7):1303-10. Sepsis Incidence Rate per 10,000 Population 50 Hospitalizations with septicemia or sepsis Hospitalizations for septicemia or sepsis 40 30 20 10 0 2000 2001 2002 2003 2004 2005 Year CDC/NCHS, National Hospital Discharge Survey. 2000-2008. 2006 2007 2008 Sepsis Hospitalization by Gender Rate per 10,000 Population 300 Male Female 250 200 150 100 0 All Ages < 65 65-74 Ages in Years CDC/NCHS, National Hospital Discharge Survey. 2000-2008. 75-84 > 85 Sepsis Incidence by Race Population-Adjusted Incidence of Sepsis (No./100,000) 500 Other Black White 400 300 200 100 0 1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 Martin GS, Mannino DM, Eaton S et al. N Engl J Med. 2003;348:1546-54. Sepsis Incidence in the United States: 2000 Incidence per 100,000 250 200 150 100 50 0 Sepsis Breast Cancer Acute Multiple Myocardial Sclerosis Infarction Lung Cancer Colon Cancer AIDS Martin GS, Mannino DM, Eaton S et al. N Engl J Med. 2003;348:1546-54. SEER Cancer Statistics Review. National Cancer Institute. http://progressreport.cancer.gov/2007 HIV/AIDS Surveillance Report. Centers for Disease Control. 2001;11. Incidence & Prevalence: 2006 Chart Book on Cardiovascular and Lung Diseases. NHLBI, NIH. 2006. Turabelidze G. J Neurol Sci. 2008;269:158-62. Sepsis Length of Stay Length of Stay (Days) 10 Septicemia or Sepsis Other hospitalizations 8 6 4 2 0 All Ages < 65 Ages in Years CDC/NCHS, National Hospital Discharge Survey. 2000-2008. > 65 Sepsis Morbidity and Mortality • In severe cases, one or more organs fail. • Worst case scenario: – – – – Blood pressure drops Septic shock Multiple organ system failure Death • The number of sepsis cases per year has been on the rise: – Aging population, the increased longevity of people with chronic diseases, the spread of antibiotic-resistant organisms, an upsurge in invasive procedures and broader use of immunosuppressive and chemotherapeutic agents. http://www.nigms.nih.gov/Education/factsheet_sepsis.htm Sepsis Mortality Mortality Rate1 Sepsis 10-20% Severe sepsis 20-50% Septic shock 40-80% • Mortality rates increase by 10% for every hour without antibiotics.2 • Survivors show continued impaired quality of life after 2 years.3 1Martin GS. Expert Rev Anti Infect Ther. 2012;10:701-6. A, Roberts D, Wood KE, et al. Crit Care Med. 2006;34(6):89–1596. 3Winters BD, Eberlein M, Leung J et al. Crit Care Med. 2010;38(5):1276-83 2Kumar Financial Implications • Annual care for hospital patients with severe sepsis averaged approximately $14 billion in 2008.1 Billion ($) • Some facilities spend as much as $24 billion annually.2 16 14 12 10 8 6 4 2 0 1997 1HCUP 2Lagu 2002 2008 Facts and Figures, 2006: Statistics on Hospital-Based Care in the United States. Rockville (MD)2008. T, Rothberg MB, Shieh MS et al. Crit Care Med. 2012 Mar;40(3):754-61. Sepsis Biomarkers Use in Diagnosis, Risk, and Response Diagnosis of Sepsis • Bacteria in the blood or other body fluids – Source of the infection – A high or low white blood cell count – A low platelet count – Low blood pressure – Too much acid in the blood (acidosis) – Altered kidney or liver function • Biomarkers Sepsis Biomarkers: Screening • Diagnosis of sepsis and evaluation of its severity is complicated by the highly variable and non-specific nature of signs and symptoms. • Distinguishing patients with localized infections or SIRS from those with sepsis is challenging. • SIRS is not specific to sepsis and can result from other conditions such as acute pancreatitis and immunodeficiencies. • Biomarkers of sepsis may improve diagnosis and therapeutic decision making. Lever A, Mackenzie I. Br Med J. 2007;335:879–83. Sepsis Biomarkers • More than 170 biomarkers have been assessed for sepsis prognosis and diagnosis. • Some common biomarkers include: – Procalcitonin (PCT) – Interleukins and other cytokines – C-reactive protein (CRP) – sCD163 – Serum lactate – sTREM Pierrakos C, Vincent JL. Crit Care. 2010,14:R15. Procalcitonin and C-Reactive Protein Procalcitonin Release of PCT into the bloodstream depends on sepsis severity. Dropping PCT levels indicate increased survival rates. Persistent elevated PCT is predictive for an unfavorable outcome. More favorable kinetic profile than other markers: levels increase 4-12 hours after onset of infection. C-Reactive Protein Can also be elevated in non-sepsis conditions. Both pro and anti-inflammatory effects. Secretion starts 4 hours after infection and peaks at 36 hours. Used to diagnose multiple infections. Ability to discriminate patients with and without sepsis is moderate. May be able to stratify risk early (day 1) but not as effective as other markers such as PCT or sTREM-1. Bloos F & Reinhart K. Virulence. 2014;5:154-60. Serum Lactate and Interleukins Interleukin-62 Serum Lactate Most widely used biomarker for organ dysfunction. 1 Faix 2 Systemic inflammation and infection increases lactate levels. Intermediate to high serum lactate levels indicate increased risk. Reference ranges for serum lactate levels may be too high for sepsis. Most goal-directed resuscitation is based on initial lactate levels and clearance. Appears rapidly and reaches peak levels within 2 hours. May have similar discriminating power to PCT. Levels related to severity and outcomes in sepsis patients. Levels decrease with controlled infection. Lack of large-scale studies to determine clinical value. J. Crit Rev Clin Lab Sci. 2013;50:23-36. Bloos F & Reinhart K. Virulence. 2014;5:154-60. sCD163 and sTREM-1 sCD163 Increases seen at the beginning of infection. Applicable in early sepsis diagnosis. Independent risk factor for sepsis survival. Prognostic in sepsis and SIRS. Lack of large-scale studies to determine clinical value. sTREM-12 Upregulated after exposure to bacteria or fungi. Non-survivors of sepsis have higher levels than survivors. Sensitivity and specificity similar to PCT. Is elevated in other inflammatory conditions. Lack of large-scale studies to determine clinical value. 1 Su 2 L, Feng L, Song Q et al. Mediators Inflamm. 2013;2013:969875. Bloos F & Reinhart K. Virulence. 2014;5:154-60. Laboratory Assays for Sepsis Assay Measurement Lactate* (mg/dl) Septic shock (n = 2) Uncomplicated sepsis (n = 19) No Sepsis (n = 45) P-Value 2.8 1.7 (1.40–2.20) 1.1 (0.73–1.55) 0.06 MRproADM (nmol/l) 1.05 (1.05–1.05) 0.91 (0.55–1.26) 0.82 (0.52–1.18) 0.78 MRproANP (pmol/l) 201 (102–300) 178 (91.6–232) 143 (77.2–349) 0.98 PCT (ng/ml) 0.34 (0.26–0.43) 0.32 (0.19–1.17) 0.18 (0.07–0.54) 0.04 Copeptin (pmol/l) 13.4 (13.1–13.7) 13.2 (6.29–34.1) 17.1 (8.2–34.8) 0.61 proET-1 (pmol/l) 118 (104–132) 75 (36.9–111) 80 (51.5–106) 0.53 All values are expressed as median (interquartile range) or % (number) accordingly. MRproADM, midregional proadrenomedullin; MRproANP, proatrial natriuretic peptide; PCT, procalcitonin; proET-1, proendothelin-1. * Only available in 14 patients (septic shock = 1, uncomplicated sepsis = 7, no sepsis = 4). Hicks CW, Engineer R, Benoit JL et al. Eur J Emerg Med. 2014;21:112-7. PCT ROC Curve for Final Diagnosis of Sepsis 1.0 0.9 True Positive Sensitivity 0.8 0.7 0.6 0.5 AUC = 0.67 0.4 0.3 0.2 0.1 0.0 0.0 0.2 0.4 0.6 0.8 1.0 1=Specificity False Positive Adapted from Hicks CW, Engineer R, Benoit JL et al. Eur J Emerg Med. 2014;21:112-7. Procalcitonin Reference Range Normal subjects < 0.5 pg/ml Chronic inflammatory processes and autoimmune diseases < 0.5 pg/ml Viral infections < 0.5 pg/ml Mild to moderate localized bacterial infections < 0.5 pg/ml SIRS, multiple trauma, burns Severe bacterial infections, sepsis, multiple organ failure 0.5 – 2 pg/ml > 2 pg/ml (often 10 – 100 pg/ml) ACCP/ Society of Critical Care Medicine Consensus Conference. Crit Care Med. 1992;20:864-74. Harbarth S, Holeckova K, Froidevaux C et al. Am J Respir Crit Care Med. 2001;164:396-402. Christ-Crain M, Jaccard-Stolz D, Bingisser R et al. Lancet. 2004;363:600-7. Survival Curves in Severe Sepsis and Septic Shock: Baseline Cortisol and Post-ACTH Basal Plasma Cortisol Level 34 g/dL, max > 9 g/dL Probability of Survival 1.00 0.80 Basal Plasma Cortisol Level 34 g/dL, max 9 g/dL or Basal Plasma Cortisol Level > 34 g/dL, max > 9 g/dL 0.60 0.40 0.20 Basal Plasma Cortisol Level > 34 g/dL, max 9 g/dL 0 0 7 14 21 Time (Days) Annane D, Sebille V, Troche G et al. J Am Med Assoc. 2000;283:1038-45. 28 CRP Levels Correlate With Mortality and Organ Failure in Sepsis 30 CRP Day 0 CRP Day 2 * 30 Survivors Non-Survivors p = 0.001 p = 0.002 CRP mg/dL CRP mg/dL * p < 0.05 20 10 0 0 1 2 (116/115) (111/110) (56/56) 3 >4 (20/19) (4/4) Number of Organ Failures Lobo SM, Lobo FR, Bota DP et al. Chest. 2003;123:2043-9. 20 10 0 Day 0 Day 2 Survivors vs. Non-Survivors Lactic Acidosis Anaerobic Glycolysis Aerobic Glycolysis (Cytoplasm) (Mitochondria) O2 Glycogen Glucose Pyruvate Citric Acid Cycle CO2 H2O Lactate 1 Glu + 2 ADP + 2 Pi 1 Glu + 6 O2 + 38 ADP + 38 Pi 2 Lactate + 2 ATP 6 CO2 + 6 H20 + 38 ATP Mizock BA, Falk JL. Crit Care Med. 1992;20:80-95. Diagnostic and Therapeutic Markers 80 60-80% Normal 60 40 50% Lactic Acidosis (≥ 4 mmol/L) SvO2 Serum Lactate as a Predictor of Mortality 50 28% 25 20 15 10 5 0 0-2.4 2.5-3.9 > 4.0 28 day in-hospital mortality 2 Shapiro 38-40% 40 30 20 10.0 0.0 Lactate1 1 Trzeciak % of Mortality Rate % of Mortality Rate 30 0-2.4 2.5-3.9 > 4.0 N = 827 N = 238 N = 112 Initial Lactate (mmol/L)2 Death within 3 days S, Dellinger RP, Chansky ME et al. Intensive Care Med. 2007;33:970-7. NI, Howell MD, Talmor D et al. Ann Emerg Med. 2005; 45:524-8. Serum Lactate as a Predictor of Mortality Mean Lactate Level (mmol/L) 7 Non-survival Survival 6 5 p = 0.001 4 p < 0.001 3 2 1 0 Arrival Scene (T1) Emergency Department (T2) Jansen TC, van Bommel J, Mulder PG et al. Crit Care. 2008,12:R160. Value of Blood Lactate Levels First Lactate Measurement N = 124 < 3.5 mmol/l 11 Missing (0 Died) Second Lactate Measurement 8/66 (12%) Mortality ≥ 3.5 mmol/l p < 0.001 24/58 (41%) Mortality 7 Missing (4 Died) N = 55 < 3.5 mmol/l 8/54 (15%) Mortality N = 51 ≥ 3.5 mmol/l < 3.5 mmol/l 0/1 (0%) Mortality 2/14 (14%) Mortality p = 1.00 18/37 (49%) Mortality p = 0.025 N = 106 Second Lactate Cumulative ≥ 3.5 mmol/l < 3.5 mmol/l 10/68 (15%) Mortality ≥ 3.5 mmol/l p < 0.001 18/38 (47%) Mortality Adapted from Jansen TC, van Bommel J, Mulder PG et al. Crit Care. 2008,12:R160. Lactate, SBP, and Mortality 60 Mortality (%) 50 40 30 20 10 0 > 3.5 < 100 SBP (mmHg) > 100 < 3.5 Jansen TC, van Bommel J, Mulder PG et al. Crit Care. 2008,12:R160. Lactate (mmol/l) Serum Lactate and Mortality in Severe Sepsis • Initial serum lactate • High initial serum lactate associated with ↑ mortality regardless of presence of shock or MODS. 45 28-Day Mortality (%) evaluated in 839 adults admitted with severe sepsis. p = 0.001 50 40 35 p = 0.022 p < 0.001 30 25 20 p = 0.024 15 10 5 0 Low Int High Low Int High Non-Shock Shock Mikkelsen ME, Miltiades AN, Gaieski DF et al. Crit Care Med. 2009;37:1670-7. Improving Lactate a Good Prognostic Sign Lactate (mmol/L) 8 6 p < 0.05 Non-survivors p < 0.05 4 p < 0.01 Survivors 2 0 INITIAL +8h +16h +24h Time Bakker J, Gris P, Coffernils M et al. Am J Surg. 1996;171:221-6. FINAL Sepsis Testing and Results Guidelines, Algorithms, and Protocols Factors to Consider When Evaluating Sepsis • Blood gases • Electrolytes • Glucose • Hematocrit • Lactate Sepsis Resuscitation Bundle The Sepsis Resuscitation Bundle is published by the Surviving Sepsis Campaign and is used by multiple hospitals across the country. The goal is to perform all indicated tasks 100% of the time within the first 6 hours of identification of severe sepsis. Surviving Sepsis Campaign. http://sccm.org Within 6 Hours Within 3 Hours Sepsis Resuscitation Bundle 1. Measure serum lactate. 2. Obtain blood cultures prior to antibiotics (best within 45 minutes). 3. Administer a broad-spectrum antibiotic, within 1 hour if possible. 4. In the event of hypotension deliver an initial minimum of 30 mL/kg of crystalloid or an equivalent. 5. Apply vasopressors for hypotension not responding to initial fluid resuscitation to maintain mean arterial pressure (MAP) > 65 mmHg. 6. In the event of persistent hypotension despite fluid resuscitation (septic shock) and/or lactate > 4 mmol/L: a. Achieve a central venous pressure (CVP) of 8-12 mmHg. b. Achieve a central venous oxygen saturation (ScvO2) > 70% or mixed venous oxygen saturation (SvO2) > 65%. 7. Re-measure serum lactate. Surviving Sepsis Campaign. http://sccm.org Sepsis Management Bundle Efforts to accomplish these goals should begin immediately, but these items may be completed within 24 hours of presentation for patients with severe sepsis or septic shock. The tasks are: 1. Administer low-dose steroids for septic shock in accordance with a standardized ICU policy. If not administered, document why the patient did not qualify for low-dose steroids based upon the standardized protocol. 2. Administer recombinant human activated protein C (rhAPC) in accordance with a standardized ICU policy. If not administered, document why the patient did not qualify for rhAPC. 3. Maintain glucose control > 70 mg/dL, but < 150 mg/dL. 4. Maintain a median inspiratory plateau pressure (IPP) < 30 cm H2O for mechanically ventilated patients. Surviving Sepsis Campaign. http://sccm.org Polymerase Chain Reaction • Polymerase chain reaction (PCR)-based assays facilitate the detection of pathogens in the blood in a few hours. • Benefits – Correlates with blood cultures – Acceptable rate of false-positives – Higher diagnostic sensitivity – Shorter evaluation time leads to earlier diagnosis Wellinghausen N, Kochem AJ, Disque C et al. J Clin Microbiol. 2009; 47(9): 2759-65. Point-of-Care Analyte Benefits • A 2010 study published in the Journal of Emergency Medicine found that point-of-care testing provided a reliable and feasible way to measure serum lactate at the bedside.1 • Base excess (BE) – Some studies suggest BE is an accurate marker for the prediction of elevated lactate in the emergency department (ED).2 – Some studies also show poor correlation due to effects of other conditions.3 • Point-of-care lactate is useful in the diagnosis of sepsis at the bedside – Recommended for institutions where clinical decisions are limited by lack of laboratory infrastructure or reliability.4 1 Shapiro NI, Fisher C, Donnino M et al. J Emerg Med. 2010;39:89-94. Montassier E, Batard E, Segard J et al. Am J Emerg Med. 2010. Epub ahead of print. 3 Martin MJ, FitzSullivan E, Salim A et al. Am J Surg. 2006;191:625-30. 4 Moore CC, Jacob ST, Pinkerton R et al. Clin Infect Dis. 2008;46:215-22. 2 Point-of-Care Analyte Testing • Single-use, self-calibrating, 100-150 uL WB sample • pH, pCO2, pO2, Na, K, iCa, Glu, Hct (plus calculated values TCO2, HCO3, BE, sO2, Hb) • Analytes on a single test card • Requires only room temperature storage* • Bar-coded for patient safety – Cant use expired cards* – Smart card technology • Low-cost test cards – < $ than benchtop systems *unique market features Turnaround Time • Serum lactate must be available with rapid turnaround time (within minutes) to effectively treat severely septic patients. • An arterial blood gas analyzer located in the clinical laboratories usually accomplishes this. • Hospitals should invest in adequate equipment in to meet present standards of care for septic patients. • If a central analyzer is not efficient in a particular hospital setting, point-of-care analyzers should be evaluated for faster turnaround time. http://www.survivingsepsis.org/bundles www.emcrit.org/wp-content/uploads/lactate-faq.pdf Time and Cost for Measuring Blood Lactate Chiron Accusport® Central Laboratory Time of transportation (min) -- -- 9.6 ± 3.8 Time for results (min) 1 1 85 ± 35 1-10 1 45-168 Electrodes: 4 x $134 Total: $536 Device: $156 -- -- Test strip: $1.22 Quality Control Bottle: $11.10 -- Costs for 197 samples $536 $248 $493 Costs of transportation of one sample -- -- $3.61 Time for results (range) Hardware Reagents Boldt J, Kumle B, Suttner S et al. Acta Anaesthesiol Scand. 2001;45:194–9. 2012 Guideline Updates • Two sets of blood cultures drawn prior to antimicrobial therapy and give antimicrobials within 1 hour of diagnosis. • One set of culture drawn percutaneously and one set drawn through each vascular access device, unless if the device was inserted within 48 hours. • If the blood culture drawn from the vascular access device turns positive ≥ 2 hours before the peripheral blood culture, data supports that the vascular access device is the source of the infection. • Initial empiric broad spectrum antimicrobial therapy (selected to cover all suspected organisms) within 1 hour after recognition of septic shock and severe sepsis without septic shock. • Mortality rises every hour without antimicrobials. Dellinger RP, Levy MM, Rhodes A et al. Crit Care Med. 2013;41(2):580-637. 2012 Guideline Updates • Antimicrobial regiment should be reassessed daily for de‐escalation. Empiric combination therapy should not be administered for > 3‐5 days. De-escalate to most appropriate single therapy pending susceptibility as soon as possible. • If invasive candidiasis suspected, send 1,3 beta‐D‐glucan assay (2D), mannan and anti‐mannan antibody assay (2C). • Suspect viral, start antiviral. Test for seasonal variations. • Use procalcitonin level or other markers to consider discontinuation of e mpiric antibiotic for those who was initially diagnosed septic, but have no subsequent evidence of infection. • Duration of therapy typically 7‐10 days. • No antimicrobial therapy if patient’s severe inflammatory state is not due to infectious causes. Dellinger RP, Levy MM, Rhodes A et al. Crit Care Med. 2013;41(2):580-637. CCF Sepsis Flowchart SIRS + Suspected Infection SIRS 2 Criteria • T > 38° or < 36° • HR > 90 • RR > 20 or PaCO2 32 mmHg • WBC > 12 K or < 4 K; Bands > 10% Identification Lactate POC (< 15’) Fluid Bolus Organic Dysfunction SBP < 90 p bolus Lactate > 4 No Sepsis Yes Rapid CV Abs Severe Sepsis/ Septic Shock Labs Cultures Mechanical Ventilation Initiate Sepsis Bundle Central Venous Arterial Line Access (< 2°) CVP < 8 Preload NS 500 cc IVB until CVP > 8 CVP > 15 + MAP > 110 NTG 10-60 mcg/min until CVP < 12 or MAP < 110 MAP < 65 Norepinephrine 2-20 mcg/min or Dopamine 5-20 mcg/kg/min MAP > 110 NTG 10-60 mcg/min until MAP < 90 or Hydralazine 10-40 mg IV EGDT Afterload Central Venous Oxygen Content ScvO2 < 70% Hgb ScvO2 No Bundled Therapies Antibiotics (< 4°) Goals Achieved ? Hgb < 10 ScvO2 < 70% • CVP 8-12 • MAP 65-110 • ScvO2 > 70% • Lactate improved APACHE III > 25 Activated Protein C Rivers EP. N Engl J Med. 2001;345:1368-77. Glycemia Control 80-110 Semirecumbent Position Transfuse PRBC Dobutamine 2.5-20 mcg/kg/min Risk Stratification • APACHE II1 • Mortality in Emergency Department Score (MEDS)2-3 • Procalcitonin-based algorithms4 • BC sepsis guidelines algorithm5 1 Giamarellos-Bourboulis EJ, Norrby-Teglund A, Mylona V et al. Crit Care. 2012;16:R149. E. Em Med Pract. 2011;11(5). 3Hermans MAW, Leffers P, Jansen LM et al. Emerg Med J. 2012;29:295-300. 4 Kopterides P, Siempos II, Tsangaris I et al. Crit Care Med. 2010;38(11):2229-41. 5 Sepsis Guide. BC Sepsis Network. www.bcpsqc.ca Accessed 03/22/14. 2 Booker Protocols Reduce Mortality • Sepsis protocols improve clinical outcomes and mortality rates • Sepsis Bundle • Hospital-specific protocols – Sepsis guideline based – Early goal directed therapy – Rapid delivery of antibiotics Surviving Sepsis Campaign. http://sccm.org Talmor D, Greenberg D, Howell MD et al. Crit Care Med. 2008;36(4):1168-74. Sepsis Identification, Treatment, and Outcomes Identification of Sepsis Are any two of the following SIRS criteria present and new to the patient? Heart rate > 90 beats/min Respiratory rate > 20/min Temperature < 36.0 or > 38.3C Acutely altered mental state Blood glucose > 7.7 mmol/L (in absence of diabetes) White cell count < 4 or > 12 x 109/L If YES, patient has SIRS Is there a clinical suspicion of new infection? Cough/sputum/chest pain Dysuria Abdominal pain/distension/diarrhea Headache with neck stiffness Line infection Cellulitis/wound/joint infection Endocarditis If YES, patient has Sepsis Is there evidence of any organ dysfunction? Systolic BP < 90/mean < 65 mmHg Urine output < 0.5 mL/kg/h for 2 h Lactate > 2 mmol/L after initial fluids Creatinine > 177 umol/L INR > 1.5 or aPTT > 60 s Platelets < 100 x 109/L Bilirubin > 34 umol/L SpO2 > 90% unless O2 given If YES, patient has Severe Sepsis Daniels R. J Antimicrob Chemother. 2011;66(Suppl 2):ii11–ii23. Treatment of Sepsis • Early goal-directed therapy: standard operating procedure – Apply with critical care/sepsis team if patient remains hypotensive or lactate remains high following fluid challenges 1. Site central venous catheter using ultrasound guidance where practicable, according to proper procedures for infection control 2. If central venous pressure (CVP) < 8 mmHg, give further fluid challenges to achieve a target CVP of > 8 mmHg (> 12 mmHg if ventilated) unless the patient shows signs of fluid overload 3. If patient remains hypotensive, start a norepinephrine infusion to target SBP > 90 mmHg or MBP > 65 mmHg. Daniels R. J Antimicrob Chemother. 2011;66(Suppl 2):ii11–ii23. Sepsis Outcomes • Lactate clearance is associated with improved patient outcome. • Lactate measurement is associated with increased risk of death independent of other aspects of sepsis bundle guidelines. • Point-of-care measurements of lactate are faster than central laboratories. – May be beneficial for serial measurements. Nguyen HB, Rivers EP, Knoblich BP et al. Crit Care Med. 2004;32(8):1637-42. Afessa B, Keegan MT, Schramm GE et al. Crit Care Med. 2011;15(Suppl 1): P286. Boldt J, Kumle B, Suttner S et al. Acta Anaesthesiol Scand. 2001;45:194–9. Conclusion